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Sustained off-treatment immune control is achievable in a proportion of patients with chronic
hepatitis B treated with peginterferon alfa-2a. We evaluated on-treatment predictors of hep-
atitis B surface antigen (HBsAg) clearance 3 years after peginterferon alfa-2a treatment and
determined the incidence of hepatocellular carcinoma.
Methods
A prospective, international, multicenter, observational study in patients with chronic hepati-
tis B who have been prescribed peginterferon alfa-2a (40KD) in a real-world setting. The pri-
mary endpoint was HBsAg clearance after 3 years’ follow-up.
Results
The modified intention-to-treat population comprised 844 hepatitis B e antigen (HBeAg)-
positive patients (540 [64%] completed 3 years’ follow-up), and 872 HBeAg-negative
patients (614 [70%] completed 3 years’ follow-up). At 3 years’ follow-up, HBsAg clearance
rates in HBeAg-positive and HBeAg-negative populations, respectively, were 2% (16/844)
and 5% (41/872) in the modified intention-to-treat population and 5% [16/328] and 10% [41/
394] in those with available data. In HBeAg-positive patients with data, Week 12 HBsAg lev-
els <1500, 1500–20,000, and >20,000 IU/mL were associated with HBsAg clearance rates
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at 3 years’ follow-up of 11%, 1%, and 5%, respectively (Week 24 predictability was similar).
In HBeAg-negative patients with available data, a�10% decline vs a <10% decline in
HBsAg at Week 12 was associated with HBsAg clearance rates of 16% vs 4%. Hepatocellu-
lar carcinoma incidence was lower than REACH-B (Risk Estimation for Hepatocellular Car-
cinoma in Chronic Hepatitis B) model predictions.
Conclusions
Sustained off-treatment immune control is achieved with peginterferon alfa-2a in a real-
world setting. HBsAg clearance 3 years after completion of peginterferon alfa-2a can be pre-
dicted on the basis of on-treatment HBsAg kinetics.
Introduction
Patients with chronic hepatitis B (CHB) are at increased risk of cirrhosis, hepatocellular carci-
noma (HCC), and liver-related death [1], and CHB is estimated to be responsible for 0.5–1
million deaths each year [2].
The goal of therapy is to prevent disease progression, and the ideal endpoint is sustained
off-treatment hepatitis B surface antigen (HBsAg) loss [2]. Current treatment options include
nucleos(t)ide analogs (NAs) and interferons. NAs suppress hepatitis B virus (HBV) DNA repli-
cation and are well tolerated, but relapse occurs frequently after withdrawal of therapy and
HBsAg loss is rare [3]; therefore, NA therapy must be continued for life to remain effective in
the majority of patients [2, 4].
Durable off-treatment responses are more likely after a finite course of treatment with
peginterferon alfa-2a. Approximately one-third of patients had sustained responses 24 weeks
after the end of treatment (EOT) with peginterferon alfa-2a in phase 3 studies [5, 6]. HBsAg
levels decreased in many patients during treatment and the extent of reduction in HBsAg was
associated with durable serologic response [7–9].
Available data suggest that HBsAg clearance is durable after treatment with peginterferon
alfa-2a in some patients [10–12]. The real-world S-Collate study assessed, in routine clinical
practice, on-treatment predictors of HBsAg clearance 3 years after cessation of treatment with
peginterferon alfa-2a.
Materials and methods
S-Collate was a prospective, international, multicenter, observational study in patients with
CHB prescribed peginterferon alfa-2a (40KD) according to the standard of care and label in
each country. Patients co-infected with hepatitis A or C or HIV were ineligible. Peginterferon
alfa-2a dosing and treatment duration were at the physician’s discretion. First patient enroll-
ment was April 11, 2009, with last follow-up November 17, 2014. Due to an administrative
delay, the study was registered with clinicaltrials.gov (NCT01011738) in November 2009, after
the first patient had been recruited. The authors confirm that all ongoing and related trials for
this drug/intervention are registered.
Assessments and follow-up
Assessments as part of routine care in accordance with current guidelines and the local stan-
dard of care were documented in an electronic case report form during and for up to 3 years
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after EOT. Patients withdrawn from treatment remained under observation with data collec-
tion, if possible, even after receiving other therapy(ies) for CHB.
The primary efficacy endpoint was HBsAg clearance (proportion of patients HBsAg-nega-
tive 3 years post-treatment). Secondary efficacy endpoints included the proportion of patients
with HBsAg <1000, <100, and<10 IU/mL, HBsAg seroconversion, and HBV DNA<2000
IU/mL and alanine aminotransferase (ALT) normalization (ALT at or below upper limit of
normal for the local laboratory) over time (0.5, 1, 2, and 3 years post-treatment). Secondary
endpoints in hepatitis B e antigen (HBeAg)-positive patients were HBeAg loss and seroconver-
sion, and the combined endpoint of HBeAg seroconversion and HBV DNA <2000 IU/mL
over time. The combined endpoint of HBV DNA<2000 IU/mL and normal ALT over time
was a secondary endpoint in HBeAg-negative patients. All laboratory assays were conducted
locally.
The incidence of HCC, diagnosed according to standard practice in each country, was a
secondary endpoint. To compare incidence with that expected in this population, expected
incidence was calculated according to the risk function of the REACH-B (Risk Estimation for
Hepatocellular Carcinoma in Chronic Hepatitis B) model, which uses baseline clinical charac-
teristics (gender, age, ALT level, HBeAg status, and HBV DNA level) to predict risk at 3, 5, and
10 years [13]. Assuming a Weibull distribution for time to HCC, the risk was calculated for up
to 4 years in all patients for whom sufficient baseline data were available, and was extrapolated
to the overall population.
Safety was assessed using adverse event (AE) data and by other clinical endpoints associated
with CHB.
The protocol and patient materials were approved by independent ethics committees at
each center (S1 Appendix) before recruitment of any patients. The study was conducted in
accordance with the principles of the Declaration of Helsinki and Good Pharmacoepidemiol-
ogy Practices [14]. All patients provided written informed consent.
Statistical considerations
Assuming a HBsAg clearance rate of 9–12% at 3 years post-treatment [15, 16], planned enroll-
ment was 1600–2000 patients (600–800 HBeAg-negative and 1000–1200 HBeAg-positive) and
the 95% confidence interval (CI) for HBsAg clearance was expected to be ±1.25% to ±1.56%.
The modified intention-to-treat (mITT) population comprised adults classified as HBeAg-
positive or HBeAg-negative who received at least one dose of peginterferon alfa-2a. Data were
analyzed using two methods: firstly, patients with missing variables for the endpoint in ques-
tion were included in the analysis and considered non-responders; secondly, analysis was
restricted to patients with available data for the endpoint in question (mITT with available
data). The safety population included all patients who received�1 dose of peginterferon alfa-
2a with�1 post-baseline safety assessment.
Data in HBeAg-positive and HBeAg-negative patients were analyzed separately using SAS
software version 9.4. Associations between baseline and on-treatment factors and HBsAg
clearance were explored by univariate and multiple logistic regression (MLR). Baseline factors
included age, sex, body weight, body mass index, race (Chinese [China or Hong Kong] vs non-
Chinese), main treatment regimens, ALT ratio, HBsAg, and HBV DNA levels. On-treatment
factors (at Weeks 12 and 24) included HBsAg, drop in HBsAg (log10), HBV DNA, and drop in
HBV DNA (log10). For selection of the factors to be included in the MLR the Least Absolute
Shrinkage and Selection Operator (LASSO) method was applied considering the optimal mod-
els to be those with the lowest Schwarz Bayesian criterion (SBC). The area under the receiver
PLOS ONE S-Collate: Observational study of peginterferon alfa-2a in patients with chronic hepatitis B
PLOS ONE | https://doi.org/10.1371/journal.pone.0230893 April 10, 2020 3 / 16
Novartis, Roche, Roche Diagnostics, Siemens,
Transgene, ViiV. All authors disclose medical
writing support from F. Hoffmann-La Roche Ltd.
This does not alter our adherence to PLOS ONE
policies on sharing data and materials.
operating characteristic curve (ROC AUC) was determined for the final logistic regression
models.
A post hoc analysis investigated the impact of missing values on HBsAg clearance. General-
ized estimating equations (GEE) methods for longitudinal data with missing values were used
to estimate the HBsAg clearance rate at EOT and 0.5, 1, 2, and 3 years post-treatment in the
mITT population. For the repeated measurements an autoregressive working correlation
structure was assumed.
In addition, the fully conditional method was applied to multiple imputation for non-
monotone multivariate missing data [17, 18]. As well as HBsAg clearance, the following covar-
iates were considered: age, body mass index, alcohol consumption (yes/no), region (China/
Hong Kong vs others), duration of treatment (�48,�24 to<48, and<24 weeks) and baseline
ALT ratio, all of which were predictive for missing HBsAg values at 3 years post-treatment.
Logistic regression was used to impute missing values for longitudinal/repeated measures of
HBsAg clearance (yes/no) at EOT and 0.5, 1, 2, and 3 years post-treatment, a regression
method was used for missing continuous variables, and a discrimination function method was
used for categorical data. Multiple imputations were repeated 50 times to estimate HBsAg
clearance rates.
Results
First patient enrollment was April 11, 2009, with last follow-up November 17, 2014. Overall,
1842 patients (877 HBeAg-positive, 912 HBeAg-negative, 53 unknown HBeAg status) were
enrolled from 219 centers in 26 countries [S2 Appendix]).
The mITT population comprised 844 HBeAg-positive (540 [64%] completed 3 years’ fol-
low-up), and 872 HBeAg-negative patients (614 [70%] completed 3 years’ follow-up) (Fig 1).
Baseline characteristics are shown in Table 1.
Peginterferon alfa-2a monotherapy was the most common regimen, administered to 697/
844 (83%) HBeAg-positive and 753/872 (86%) HBeAg-negative patients (S1 Table). Treatment
duration was 48 weeks in 379/844 (45%) HBeAg-positive and 628/872 (73%) HBeAg-negative
patients.
Among HBeAg-positive patients, 697 (83%) received peginterferon alfa-2a monotherapy,
28 (3%) received combination peginterferon alfa-2a plus NA therapy, 30 (4%) received pegin-
terferon alfa-2a add-on therapy, and 89 (11%) received another regimen, while 549 (65%)
received treatment for at least 48 weeks, with 149 (18%) treated for 72 weeks or longer. Among
HBeAg-negative patients, 753 (86%) received peginterferon alfa-2a monotherapy, 31 (4%)
received combination peginterferon alfa-2a plus NA therapy, 47 (5%) received peginterferon
alfa-2a add-on therapy, and 41 (5%) received another regimen, while 692 (79%) received treat-
ment for at least 48 weeks, with 70 (8%) treated for 72 weeks or longer (S1 Table).
Efficacy in HBeAg-positive patients
The proportion of patients with a virologic response (HBV DNA<2000 IU/mL), HBeAg sero-
conversion, and a combined response is shown in Fig 2. In the mITT population, 11% had a
combined response at EOT and 5% after 3 years’ follow-up (Fig 2A). Excluding patients with
missing measurements, these rates were 20% at EOT and 15% after 3 years’ follow-up (Fig 2B).
HBsAg <1500 IU/mL at Weeks 12 or 24 of treatment was associated with higher rates of
HBeAg seroconversion and combined response rates (Table 2).
The HBsAg clearance rate 3 years post-treatment was 2% (16/844) (95% CI 1–3) in the
mITT population, and 5% (16/328) (95% CI 3–8) in patients with available data (Fig 3).
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HBsAg clearance rates in patient subgroups are shown in S2 Table. Of 16 HBeAg-positive
patients with HBsAg clearance, 14 had received peginterferon alfa-2a monotherapy.
HBsAg clearance was higher in patients with HBsAg <1500 IU/mL at Weeks 12 (11%) or
24 of treatment (11%) than in patients with higher HBsAg levels at these time points (Table 2).
Among pre-treatment and on-treatment factors analyzed for prediction of HBsAg clearance
at 3 years post-treatment (mITT population) using LASSO selection followed by MLR model
inspection, only log10 HBsAg at Week 24 remained as significant predictor (odds ratio [OR]
0.386, 95% CI 0.236–632, P = 0.0001; ROC AUC = 0.802). Addition of log10 drop in HBV
Fig 1. Patient disposition. HBeAg, hepatitis B e antigen; mITT, modified intention-to-treat. aFrom start of treatment to last dose. bFrom last dose to last contact.
cSeven patients (five HBeAg-positive; two HBeAg-negative) were receiving ongoing therapy at study end.
https://doi.org/10.1371/journal.pone.0230893.g001
Table 1. Baseline disease and demographic characteristics in the mITT population.
Characteristic HBeAg-positive n = 844 HBeAg-negative n = 872
Male sex, n (%) 592 (70) 644 (74)
Age, years 31.2 (9.3) 38.0 (10.8)
Race, n/N (%)
Asian 640/796 (80) 285/731 (39)
White 138/796 (17) 419/731 (57)
Black 11/796 (1) 25/731 (3)
Other 7/796 (<1) 2/731 (<1)
BMI, kg/m2 23.3 (3.7), n = 829 25.0 (4.0), n = 860
Previous interferon therapy, n (%) 71 (8) 75 (9)
Previous nucleos(t)ide therapy, n (%) 156 (18) 131 (15)
Hepatitis D virus co-infection, n/N (%) 8/369 (2) 28/485 (6)
HBV DNA, log10 IU/mL 6.25 (1.70), n = 732 4.53 (1.72), n = 757
HBsAg, log10 IU/mL 3.94 (0.77), n = 354 3.45 (0.85), n = 370
ALT, IU/L 179 (152), n = 834 118 (111), n = 846
ALT ratio x ULN 3.3 (2.8), n = 834 2.1 (2.0), n = 846
Genotype, n/N (%)
A 22/242 (9) 35/220 (16)
B 43/242 (18) 23/220 (10)
C 94/242 (39) 17/220 (8)
D 67/242 (28) 116/220 (53)
Other 16/242 (7) 29/220 (13)
Method to assess liver fibrosis, n (%)
Biopsy (invasive) 193 (23) 349 (40)
Non-invasive method 163 (19) 183 (21)
Not assessed 488 (58) 340 (39)
Results of liver fibrosis assessment, n/N (%)
No cirrhosis 305/356 (86) 455/532 (86)
Transition to cirrhosis 37/356 (10) 50/532 (9)
Cirrhosis 14/356 (4) 27/532 (5)
FibroScan value in kPa 9.7 (6.9) n = 56 7.6 (3.5) n = 95
ALT, alanine aminotransferase; ALT ratio, individual patient’s ALT divided by the ULN for the local laboratory;
BMI, body mass index; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; ULN, upper limit of normal.
Mean (standard deviation) unless otherwise stated.
https://doi.org/10.1371/journal.pone.0230893.t001
PLOS ONE S-Collate: Observational study of peginterferon alfa-2a in patients with chronic hepatitis B
PLOS ONE | https://doi.org/10.1371/journal.pone.0230893 April 10, 2020 6 / 16
Fig 2. Response rates in HBeAg-positive patients (HBV DNA<2000 IU/mL, ALT normalization, HBeAg seroconversion, and combined
responses) and HBeAg-negative patients (HBV DNA<2000 IU/mL, ALT normalization, and combined responses) over time (mITT
population and mITT patients with available data). Patients receiving nucleos(t)ide analogs were considered to be non-responders for HBV DNA
endpoints at the respective time points. ALT response includes only patients with elevated ALT at baseline. ALT, alanine aminotransferase; HBeAg,
hepatitis B e antigen; HBV, hepatitis B virus; mITT, modified intention-to-treat; SC, seroconversion.
https://doi.org/10.1371/journal.pone.0230893.g002
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DNA from baseline to Week 12 or 24 improved the prediction model slightly, but neither vari-
able reached statistical significance in the MLR.
The proportion of patients with HBsAg <1000, <100, and<10 IU/mL decreased over time
in the mITT population (Fig 4A); however, considering only mITT patients with available
data, the proportions remained relatively stable over time, and at the end of 3 years’ follow-up,
approximately one-third of HBeAg-positive patients (32%) had HBsAg <1000 IU/mL and 8%
had HBsAg <10 IU/mL (Fig 4B). A total of 5% of HBeAg-positive patients with available data
had experienced HBsAg seroconversion after 3 years’ follow-up.
Using the GEE methods for longitudinal repeated measurements with missing values, the
HBsAg clearance rates were 6% (95% CI 4–8) at 1 year, 6% (95% CI 4–7) at 2 years, and 6%
(95% CI 4–8) at 3 years post-treatment. If multiple imputations for missing data were applied
the estimated rates were almost identical: 6% (95% CI 4–9) at 1 year, 6% (95% CI 3–8) at 2
years, and 7% (95% CI 4–10) at 3 years (S3 Table).
Efficacy in HBeAg-negative patients
In the mITT population, 31% had a combined response at EOT and 14% after 3 years’ follow-
up (Fig 2C). When patients with missing measurements were excluded, these rates were 41%
at EOT and 28% after 3 years’ follow-up (Fig 2D).
The HBsAg clearance rate 3 years post-treatment was 5% (41/872) (95% CI 3–6) in the
mITT population, and 10% (41/394) (95% CI 8–14) in patients with available data (Fig 3).
Among HBeAg-negative patients, the rate of HBsAg clearance was 4% (31/753) in those who
received peginterferon alfa-2a monotherapy, and 11% (5/47) among those who received pegin-
terferon added-on to NA therapy (S2 Table).
For patients with available data, a decline in HBsAg of�10% between baseline and Weeks
12 or 24 of treatment was associated with HBsAg clearance rates of 16% and 17%, respectively,
after 3 years’ follow-up (Table 3). In contrast, post-treatment HBsAg clearance rates in patients
with<10% decline in HBsAg between Weeks 12 and 24 of treatment were 4% and 2%, respec-
tively (Table 3).
Table 2. Response rates after 3 years’ follow-up according to HBsAg level at Weeks 12 and 24 of treatment in HBeAg-positive patients. mITT patients with available
data.
HBsAg level, IU/mL Response 3 years post-treatment, n/N (%)
HBeAg seroconversion Combined response (HBeAg seroconversion and HBV DNA <2000 IU/mL) HBsAg clearance
Week 12
<1500 18/33 (55) 12/31 (39) 4/35 (11)
1500–20,000 28/82 (34) 9/76 (12) 1/94 (1)
>20,000 13/39 (33) 3/38 (8) 2/42 (5)
P-valuea 0.0764 0.0010 0.1877
Week 24
<1500 24/44 (55) 16/40 (40) 6/55 (11)
1500–20,000 30/74 (41) 10/69 (14) 1/77 (1)
>20,000 8/34 (24) 2/33 (6) 1/35 (3)
P-valuea 0.0058 0.0002 0.0432
HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; mITT, modified intention-to-treat.
Patients with missing HBsAg values at Weeks 12 or 24 are not shown.
aTwo-sided Cochran–Armitage trend test.
https://doi.org/10.1371/journal.pone.0230893.t002
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Among on-treatment factors analyzed for prediction of HBsAg clearance at 3 years post-
treatment (mITT population) using LASSO selection followed by MLR model inspection, only
a lower HBsAg value at Week 24 remained as significant predictor (odds ratio [OR] 0.250,
95% CI 0.158–0.395, P =<0.0001; ROC AUC = 0.920). The odds of HBsAg clearance
increased fourfold (= 1/0.250) for each log10 decrease in HBsAg at Week 24.
When both pre-treatment and on-treatment predictors were considered, in addition to a
lower HBsAg at Week 24 (OR 0.247, 95% CI 0.149–0.408, P =<0.0001), only a higher baseline
ALT (OR 1.213, 95% CI 0.977–1.505, P = 0.0806) was identified as additional weak predictor,
but this did not reach statistical significance.
The proportion of patients with HBsAg <1000, <100, and<10 IU/mL decreased over time
in the mITT population (Fig 4C); however, when only patients with available data were
included, the proportions remained relatively stable over time and after 3 years’ follow-up
approximately half of HBeAg-negative patients (52%) had HBsAg <1000 IU/mL and 15% had
HBsAg <10 IU/mL (Fig 4D). A total of 9% of HBeAg-negative patients with available data had
experienced HBsAg seroconversion after 3 years’ follow-up.
Fig 3. HBsAg clearance after 3 years’ follow-up in the mITT population and mITT patients with available data. CI, confidence interval; HBeAg, hepatitis B e
antigen; HBsAg, hepatitis B surface antigen; mITT, modified intention-to-treat.
https://doi.org/10.1371/journal.pone.0230893.g003
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Fig 4. HBsAg levels, HBsAg loss, and HBsAg seroconversion over time in the mITT population and mITT patients with available data. HBeAg,
hepatitis B e antigen; HBsAg, hepatitis B surface antigen; mITT, modified intention-to-treat.
https://doi.org/10.1371/journal.pone.0230893.g004
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Using the GEE methods for longitudinal repeated measurements with missing values, the
HBsAg clearance rates were 8% (95% CI 6–10) at 1 year, 9% (95% CI 7–11) at 2 years, and 11%
(95% CI 8–14) at 3 years post-treatment. If multiple imputations for missing data were applied
the estimated rates were almost identical: 9% (95% CI 6–11) at 1 year, 8% (95% CI 5–11) at 2
years, and 11% (95% CI 8–14) at 3 years (S3 Table).
Adverse events
Among the 1801 patients in the safety population, 103 (6%) withdrew due to AEs and 1294
(72%) and 112 (6%) experienced at least one AE and serious AE (SAE), respectively (Table 4).
The most common AEs were thrombocytopenia (14%), pyrexia (13%), and neutropenia (13%)
(Table 4), consistent with the known tolerability of peginterferon alfa-2a. Depression was
reported in 69 of 1801 (4%) patients.
A total of 40 patients experienced SAEs remotely, possibly or probably related to treatment,
including 10 with hematologic events (five neutropenia, three thrombocytopenia, two anemia,
and one leukopenia), eight with hepatobiliary events, and four with psychiatric events (two
depression and two major depression).
ALT flares>5–10 x the upper limit of normal (ULN) and>10 x ULN were reported in 154
(9%) and 49 (3%) patients, respectively.
Twelve cases of HCC were detected compared with 19 expected in this population using the
REACH-B function. After 1 year of follow-up there were three cases of HCC (three expected),
after 2 years there were six cases (eight expected), and after 3 years there were nine cases (14
expected). In the 970 Asian/Oriental patients there were three cases of HCC at 4 years com-
pared with ten predicted by REACH-B. The REACH-B score was developed in patients with-
out cirrhosis and in 794 patients without cirrhosis/transition to cirrhosis there were five cases
(nine predicted). Conclusions could not be drawn due to small numbers. One patient with
HCC underwent liver transplantation.
Two patients died during treatment and 10 during follow-up (Table 4). Eleven deaths were
unrelated to study treatment; one was considered remotely related. Four deaths were due to
HCC (unrelated), one to pulmonary metastases in a patient with HCC (remotely related), and
one to hepatic coma and septic shock (unrelated). Non-hepatic causes of death included road
traffic accidents (two), cardiopulmonary arrest, ruptured cerebral aneurysm, malignant mela-
noma, and gastric cancer.
Table 3. HBsAg clearance rates after 3 years’ follow-up according to the decline in HBsAg level between baseline
and Weeks 12 and 24 of treatment in HBeAg-negative patients. mITT patients with available data.
Decline in HBsAg level from baseline HBsAg clearance 3 years post-treatment, n/N (%) P-valuea
Week 12
Any 12/89 (13) 0.0562
None 3/72 (4)
�10% 12/77 (16) 0.0128
<10% 3/84 (4)
Week 24
Any 14/94 (15) 0.0109
None 1/53 (2)
�10% 14/82 (17) 0.0018
<10% 1/65 (2)
HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; mITT, modified intention to treat
aTwo-sided Fisher exact test.
https://doi.org/10.1371/journal.pone.0230893.t003
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Discussion
This prospective, international, multicenter, observational study shows that HBsAg clearance
is durable in a proportion of HBeAg-positive and HBeAg-negative patients for up to 3 years
after completion of peginterferon alfa-2a therapy. In the mITT population, the rate of HBsAg
clearance after 3 years of follow-up was 2% (16/844) in HBeAg-positive patients and 5% (41/
872) in HBeAg-negative patients. However, when the large number of patients without infor-
mation on HBsAg clearance at 3 years’ follow-up (61% and 56%, respectively) are excluded,
the final HBsAg clearance rates were 5% (16/328) and 10% (41/394), respectively. Moreover,
HBsAg clearance rates increased over 3 years in both cohorts when multiple imputation meth-
ods were applied, and predictive covariates used to estimate HBsAg for patients with missing
values. These results indicate that the response rates in patients with available data do not over-
estimate the real response rates. It is plausible that missing HBsAg data were more frequent at
follow-up visits where HBsAg clearance was documented at the previous visit than after visits
where HBsAg remained detectable.
S-Collate included a large, diverse cohort of patients with active disease treated under con-
ditions reflecting everyday clinical practice. Data are available for 1842 HBeAg-positive and
HBeAg-negative patients infected with all major HBV genotypes from 26 countries in Africa,
Asia, Europe, the Middle East, and the Pacific region. Approximately one-quarter of the
patients had received prior treatment for CHB and many received NA in parallel or subse-
quent to treatment with peginterferon alfa-2a.
Spontaneous HBsAg clearance and seroconversion do not occur at constant rates in
untreated cohorts, but typically occur at low rates in ‘inactive carriers’ who have persistently
low or undetectable HBV DNA levels [19–21], and generally occur more commonly in
HBeAg-negative than HBeAg-positive patients [22, 23]. Thus, the observed HBsAg clearance
Table 4. AEs in the safety analysis set.
Patients, n (%) HBeAg-positive n = 863 HBeAg-negative n = 890 Totala N = 1801
Any AE 618 (72) 646 (73) 1294 (72)
Any SAE (regardless of relationship to treatment) 47 (5) 63 (7) 112 (6)
Any treatment-related SAE 18 (2) 22 (2) 40 (2)
AE leading to withdrawal 50 (6) 48 (5) 103 (6)
Death 3 (<1) 9 (1) 12 (<1)
Incidence of individual AEsb
Thrombocytopenia 54 (6) 185 (21) 248 (14)
Pyrexia 147 (17) 92 (10) 241 (13)
Neutropenia 76 (9) 153 (17) 234 (13)
Headache 84 (10) 121 (14) 212 (12)
Asthenia 64 (7) 124 (14) 195 (11)
Leukopenia 56 (6) 124 (14) 186 (10)
Fatigue 89 (10) 93 (10) 185 (10)
Alopecia 113 (13) 67 (8) 181 (10)
ALT flares on treatment
>5−10 x ULN 73 (9) 76 (9) 154 (9)
>10 x ULN 26 (3) 22 (3) 49 (3)
AE, adverse event; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; SAE, serious AE; ULN, upper limit of normal.
aIncludes 48 patients with unknown HBeAg status.
bAEs with an incidence�10%.
https://doi.org/10.1371/journal.pone.0230893.t004
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rates exceed what would be expected in this population and suggest that treatment with pegin-
terferon alfa-2a modifies the natural history of the disease in a manner that is maintained for
several years after stopping therapy.
HBsAg clearance rates increased over time when HBsAg clearance was estimated using the
multiple imputation approach. In large randomized studies, the rate of HBsAg seroconversion
6 months post-treatment was 2–7% in HBeAg-positive [5, 24, 25] and 2% in HBeAg-negative
[6] patients. HBsAg clearance after 3 years of untreated follow-up in S-Collate was somewhat
lower in HBeAg-positive than in HBeAg-negative patients and lower than seen in HBeAg-neg-
ative patients after 3–5 years in small follow-up studies [16, 26].
Most patients did not experience HBsAg clearance in S-Collate but suppression of HBsAg
below 1000, 100, and 10 IU/mL for up to 3 years post-treatment occurred in a clinically signifi-
cant proportion. In the mITT population, 7% and 11% of HBeAg-positive and HBeAg-nega-
tive patients, respectively, had HBsAg <1000 IU/mL at 3 years’ follow-up; of patients with
available data, approximately one-third and one-half, respectively, of HBeAg-positive and
HBeAg-negative patients had HBsAg <1000 IU/mL at 3 years’ follow-up.
A substantial proportion of patients had combined responses at EOT and during follow-up.
A total of 41% of HBeAg-negative patients with available data had normal ALT and HBV
DNA<2000 IU/mL at EOT, and the response rates at 1 and 3 years post-treatment were 29%
and 28%, respectively. Among HBeAg-positive patients with available data, 20% achieved
HBeAg seroconversion and HBV DNA<2000 IU/mL at EOT, and a response rate of 14–15%
was observed at 1 and 3 years post-treatment. Among patients with elevated baseline ALT,
45% had normal ALT at EOT and 80% of patients with available data had normal ALT after 3
years’ follow-up.
These results support and extend the findings of a retrospective analysis of data from
HBeAg-positive patients in a phase 3 study of peginterferon alfa-2a [27]. Patients with HBsAg
<1500 IU/mL at Weeks 12 and 24 of treatment had high HBsAg clearance rates (11–12%) 6
months post-treatment [27]. In the present study, HBsAg <1500 IU/mL at Weeks 12 or 24 of
treatment was associated with HBsAg clearance 3 years post-treatment. HBsAg<1500 IU/mL
at Week 12 has been associated with sustained immune control (HBeAg loss and HBV DNA
<2000 IU/mL) in HBeAg-positive patients [28], while HBsAg�20,000 IU/mL at Week 24 has
been associated with non-response (negative predictive value 92–98%) [28]. In the present
study, HBsAg levels <1500, 1500–20,000, or>20,000 IU/mL at Week 12 were associated with
combined response rates of 39%, 12%, and 8%, respectively, 3 years post-treatment in patients
with available data.
In HBeAg-negative patients with available data, a�10% decline in HBsAg at Weeks 12 or
24 was associated with higher HBsAg clearance rates (16% and 17%, respectively) at 3 years’
follow-up compared with patients with<10% decline (4% and 2%, respectively). A previous
long-term follow-up study [26] showed HBsAg clearance rates of 22–23% at 5 years post-treat-
ment in patients with a�10% decline in HBsAg at Weeks 12 and 24 of treatment, while in
patients without a 10% decline HBsAg clearance was 4–8%.
The safety of peginterferon alfa-2a was consistent with that reported in large randomized
studies [5, 6, 24]. The incidence of SAEs (6%) was similar to that seen in trials using the
approved dosage regimen (3–7%) [5, 6]. The low incidence of depression in the present trial
(4%) is also consistent with phase 3 studies (4–5%). ALT flares >5 x ULN were reported in 3%
of patients.
The incidence of HCC was lower in the S-Collate study than predicted by REACH-B, par-
ticularly in Asian patients and those without cirrhosis/transition to cirrhosis. However, given
the low numbers, it is not known whether the emerging difference at 4 years is a robust trend,
and studies with longer follow-up are required. The young age, small proportion with
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cirrhosis/transition to cirrhosis, and short duration of follow-up for detecting HCC also make
interpretation difficult.
A real-world study such as S-Collate has inherent limitations, including the lack of a control
group. It is not possible to state whether HBsAg clearance exceeds a baseline rate in untreated
patients or in patients treated with NA. Treatment regimens were not strictly defined and
many patients received parallel or overlapping NA treatment. Many patients had missing val-
ues, and genotype was unknown in most. Approximately 60% had no HBsAg result after 3
years’ follow-up, limiting any conclusions drawn. The results of this long-term observational
study are consistent with those of large phase 3 studies and demonstrate that sustained off-
treatment immune control is achieved in a proportion of patients treated with peginterferon
alfa-2a. After 3 years’ follow-up, 5% of HBeAg-positive and 10% of HBeAg-negative patients
with available data had experienced HBsAg clearance. Rates of HBsAg clearance increased in
HBeAg-negative patients over the 3 years after treatment, and HBsAg clearance could be pre-





S1 Appendix. Trial information.
(DOCX)
S2 Appendix. Ethical approval–list of Independent Ethics Committees (IECs) or Institu-
tional Review Boards (IRBs): S-Collate study.
(DOCX)
S3 Appendix. List of investigators: S-Collate study.
(DOCX)
S1 Table. Treatment regimens.
(DOCX)
S2 Table. HBsAg clearance rates in predefined subgroups (HBV genotype, treatment
group, treatment duration) (mITT patients with available data).
(DOCX)
S3 Table. Estimates of HBsAg clearance rates in patients with available data and after







The authors thank Blair Jarvis, MSc ELS, and John Carron, PhD, of Health Interactions, for
writing assistance, and Ina Burghaus, PhD, of PROMETRIS GmbH, for statistical analysis and
review of the manuscript.
PLOS ONE S-Collate: Observational study of peginterferon alfa-2a in patients with chronic hepatitis B
PLOS ONE | https://doi.org/10.1371/journal.pone.0230893 April 10, 2020 14 / 16
Author Contributions
Conceptualization: Patrick Marcellin, Teerha Piratvisuth, Diethelm Messinger, Georgios
Bakalos, Ulrich Alshuth, Heiner Wedemeyer.
Data curation: Patrick Marcellin, Qing Xie, Seung Woon Paik, Robert Flisiak, Teerha Piratvi-
suth, Jörg Petersen, Tarik Asselah, Markus Cornberg, Denis Ouzan, Graham R. Foster,
Georgios Papatheodoridis, Pietro Lampertico, Heiner Wedemeyer.
Formal analysis: Patrick Marcellin, Qing Xie, Robert Flisiak, Teerha Piratvisuth, Jörg Peter-
sen, Tarik Asselah, Markus Cornberg, Denis Ouzan, Graham R. Foster, Georgios Papatheo-
doridis, Diethelm Messinger, Loredana Regep, Georgios Bakalos, Ulrich Alshuth, Pietro
Lampertico, Heiner Wedemeyer.
Writing – original draft: Patrick Marcellin.
Writing – review & editing: Patrick Marcellin, Qing Xie, Seung Woon Paik, Robert Flisiak,
Teerha Piratvisuth, Jörg Petersen, Tarik Asselah, Markus Cornberg, Denis Ouzan, Graham
R. Foster, Georgios Papatheodoridis, Diethelm Messinger, Loredana Regep, Georgios Baka-
los, Ulrich Alshuth, Pietro Lampertico.
References
1. Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology,
vaccine and drugs. J Hepatol. 2015; 62(1 Suppl):S76–86.
2. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the man-
agement of hepatitis B virus infection. J Hepatol. 2017; 67(2):370–98. https://doi.org/10.1016/j.jhep.
2017.03.021 PMID: 28427875
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